Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

from http://www.acceleronpharma.com/our-company/

Patents 1,040show all

  • 267
    C07K - Peptides
  • 245
    A61K - Preparations for medical, dental, or toilet purposes
  • 60
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 40
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
  • 38
    C12N - Microorganisms or enzymes
  • 37
    C12Y - Enzymes
  • 12
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms

Clinical Trials 41show all

27Phase 27Phase 13N/A3Phase 31Other

SEC Filings show all


89
8-K

19
10-Q

6
10-K

5
D

1
S-1

Contact Information

128 Sidney Street
Cambridge, MA 02139
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$141,706,040101-2502013-09-24Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2013-09-24$10,000,005Series Unknown
2004-02-17$8,954,908Convertible Note
2010-06-10$10,250,006Series UnknownVenrock, Advanced Technology Ventures, Flagship Pioneering, Polaris Partners, OrbiMed
2004-08-10$9,050,000Series A
2011-01-06$1,500,000Grant
2011-12-23$30,000,000Series DCelgene
2009-12-15$10,951,121Series Unknown
2007-10-01$31,000,000Series CBessemer Venture PartnersMPM Capital, QVT Financial
2006-08-02$30,000,000Series BOrbiMedPolaris Partners, Flagship Pioneering, Venrock, Advanced Technology Ventures, Sutter Hill Ventures

SEC Form D Funding Events

DateOfferedSoldType
2013-09-27$10,000,005$10,000,005Equity
2012-01-04$30,472,934$30,472,934Equity
2010-07-21$11,500,005$10,250,006Equity, Option to Acquire, Security to be Acquired
2009-12-15$10,951,121$10,951,121Equity
2008-04-07Unknown Unknown Other (Paper Filing)

Key Executives

  • John Knopf
    Executive Officer, Director
  • Peter Courossi
    Executive Officer
  • Jasbir Seehra
    Executive Officer
  • Matthew L. Sherman
    Executive Officer
  • Anthony Evnin
    Director
  • Ed Kania
    Director
  • Jean George
    Director
  • Pat Gage
    Director
  • Richard Pops
    Director
  • Terry Mcguire
    Director
  • Wylie Vale
    Director
  • Tom Maniatis
    Director
  • Carl Gordon
    Director
  • Joseph S. Zakrzewski
    Director
  • George Golumbeski
    Director
  • Anthony B Evnin
    Director
  • Edwin M. Kania
    Director
  • Kevin F. Mclaughlin
    Executive Officer
  • Richard F. Pops
    Director
  • Terrance G. Mcguire
    Director
  • Wylie W. Vale
    Director
  • Carl L. Gordon
    Director
  • Robert Steininger
    Executive Officer
  • Steven Ertel
    Executive Officer
  • Edwin M. Kania, Jr.
    Director